CTRI/2023/08/057036尚未招募4 期
To Compare Safety and Efficacy of Silodosin Versus Mirabegron in Medical Expulsive Therapy for Lower Ureteric Stones - NI
Dr Rajendera Prasad Government Medical College, Kangra at Tanda, Himachal Pradesh India0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •lower distal uretric calculi of size less than or equal to 10 mm
排除标准
- •1.Patient not willing to give written informed consent.
- •2.Severe hydroureteronephrosis.
- •3.Multiple ureteric calculi.
- •4.Bilateral ureteric calculi.
- •5.Pregnancy.
- •6.Previous ureteric and bladder surgery.
- •7.Anatomical abnormalities of genitourinary tract.
- •8.Solitary functioning kidney.
- •9.Infective complications
- •10.Concurrent administration of diuretics and calcium channel blockers.
- •11.Patient allergic to study drugs
研究者
相似试验
进行中（未招募）
1 期
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseBenign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert pressure on the lumen of the prostatic urethra, resulting in a gradual obstruction to urine flow.MedDRA version: 8.1 Level: LLT Classification code 10004446EUCTR2005-005665-11-GBRecordati S.p.A1,400
进行中（未招募）
不适用
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseEUCTR2005-005665-11-FIRecordati S.p.A1,400
进行中（未招募）
1 期
Evaluation Of The Efficacy And Safety Of Silodosin Vs. Tamsulosin And Placebo In The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia. Multicentre, Randomised, Double-Blind, Controlled Trial With An Optional Long-Term Open-Label Extension PhaseBenign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate due to cellular hyperplasia of both glandular and stromal elements. As the prostate increases in size it may exert pressure on the lumen of the prostatic urethra, resulting in a gradual obstruction to urine flow.MedDRA version: 8.1Level: LLTClassification code 10004446EUCTR2005-005665-11-ESRecordati S.p.A1,400
尚未招募
3 期
Evaluate efficacy and safety of combination of Silodosin and Tadalafil vs. Silodosin or Tadalafil alone in patients with enlarged prostateCTRI/2020/07/026440I
进行中（未招募）
不适用
EVALUATION OF THE EFFICACY AND SAFETY OF SILODOSIN vs. TAMSULOSIN AND PLACEBO IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. MULTICENTRE, RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIAL WITH AN OPTIONAL LONG-TERM OPEN-LABEL EXTENSION PHASE - NDEUCTR2005-005665-11-ITRECORDATI1,400